Business
Canopy Growth to Supply Medical Cannabis Flower Strains to the UK
Add MyCannabis.com to your preferred sources on Google
Canopy Growth Corporation (CGC ) will supply four Canadian-grown medical cannabis flower strains for distribution in the United Kingdom, the company announced on September 22, 2026, extending the reach of its international cannabis business into another European market.
The flower strains will be supplied to GROW Group U.K. Ltd., described in the announcement as a manufacturer and distributor of prescribed cannabis-based medicines across Europe. GROW Group will commercialize the products in the UK under Canopy Growth’s global Spectrum Therapeutics medical brand, and the company stated that this initial launch represents the introduction of its portfolio products into the UK market. The announcement was datelined Smiths Falls, Ontario.
“Expanding availability of our products into the UK is another step in growing our European medical cannabis business and broadening the international reach of our Canadian-grown flower,” said Chief Executive Officer Luc Mongeau. He said that with an established European Union Good Manufacturing Practice (EU GMP) supply capability and growing demand across European medical markets, the company sees continued opportunity to build this part of its business through disciplined expansion into attractive markets.
EU GMP Certification at Kincardine
The company said the UK supply builds on the recent renewal of the EU GMP certification at its Kincardine, Ontario cultivation facility, which supports its ability to serve medical cannabis markets across Europe. The renewal was announced on August 14, 2026, when the facility received renewed certification from the Regierungspräsidium Tübingen – Leitstelle Arzneimittelüberwachung Baden-Württemberg. With the renewal in place, the company said it can continue supplying Canadian-grown cannabis from Kincardine to those markets.
“This renewal reflects the quality, consistency, and reliability of our cultivation operations at Kincardine and our commitment to supplying high-quality EU GMP flower directly from Canada,” Mongeau said in the August announcement. He said the company is continuing to broaden its flower portfolio as its business in Europe grows, including through the introduction of MTL Cannabis genetics and additional strains, to meet the evolving needs of patients across the region.
Canopy Growth describes Kincardine as the anchor asset of its complete end-to-end EU GMP flower supply chain, connecting Canadian-cultivated flower to European distribution capabilities through the company’s second EU GMP facility in Sankt Leon-Rot, Germany.
First-Quarter Fiscal 2027 Results
The UK arrangement follows Canopy Growth’s first-quarter fiscal 2027 results, reported on August 7, 2026 for the three months ended June 30, 2026. International markets cannabis net revenue was $9.6 million in the quarter, up 10% over the prior-year period, an increase the company attributed primarily to strength in Europe, specifically Poland. The August certification announcement likewise said momentum in Europe helped drive a 10% year-over-year increase in international cannabis net revenue in the first quarter of fiscal 2027. All financial figures in the results release are reported in Canadian dollars.
The company reported consolidated net revenue of $81.2 million for the quarter, a 13% increase over the same period a year earlier, with net revenue growth in every business. Cannabis net revenue was $65.1 million, up 14%, and Storz & Bickel net revenue was $16.1 million, up 6%. Canada medical cannabis net revenue rose 22% to $25.8 million, driven by growth in the number of insured customers and the acquisition of MTL Cannabis, partially offset by the Canadian government’s reduction in the Veterans Affairs Canada reimbursement rate for medical cannabis. Canada adult-use cannabis net revenue rose 10% to $29.7 million, primarily on increased flower sales driven by the MTL Cannabis acquisition, partially offset by declines in opportunistic bulk sales, the company reported.
Canopy Growth also reported that its adjusted gross margin improved to 31% in the quarter from 25% a year earlier, its adjusted EBITDA loss narrowed by 59% to $3.2 million, and its net loss was 68% lower than in the prior-year period; the adjusted figures are non-GAAP measures as defined by the company.
During the quarter, the company relaunched the Tweed brand in the German medical cannabis market, taking advantage of MTL Cannabis’ premium genetics and flower production capacity, and Spectrum Therapeutics introduced new 30- and 90-pack formats for its softgels with enhanced dosing options. Mongeau said in the results announcement that at the heart of the company’s cannabis strategy is a company-wide push to elevate cultivation and produce a consistent and increasing supply of high-quality flower to support growing demand both in Canada and internationally. Chief Financial Officer Tom Stewart said the integration of MTL Cannabis is leading to increased supply of high-quality flower, expanded revenue opportunities and the realization of meaningful synergies, and that the company anticipates further improvements in its financial results, especially in the second half of fiscal 2027, as the integration is completed.
